BACKGROUND AND PURPOSE: While brain MR imaging is routinely performed, the MR imaging assessment of spinal cord pathology in multiple sclerosis (MS) is less frequent in clinical practice. The purpose of this study was to determine whether measurements of medulla oblongata volume (MOV) on routine brain MR imaging could serve as a biomarker of spinal cord damage and disability in MS. MATERIALS AND METHODS: We identified 45 patients with MS with both head and cervical spinal cord MR imaging and 29 age-matched and sex-matched healthy control subjects with head MR imaging. Disability was assessed by the expanded disability status scale (EDSS) and ambulation index (AI). MOV and upper cervical cord volume (UCCV) were manually segmented; semiautomated segmentation was used for brain parenchymal fraction (BPF). These measures were compared between groups, and linear regression models were built to predict disability. RESULTS: In the patients, MOV correlated significantly with UCCV (r = 0.67), BPF (r = 0.45), disease duration (r = -0.64), age (r = -0.47), EDSS score (r = -0.49) and AI (r = -0.52). Volume loss of the medulla oblongata was -0.008 cm(3)/year of age in patients with MS, but no significant linear relationship with age was found for healthy control subjects. The patients had a smaller MOV (mean +/- SD, 1.02 +/- 0.17 cm(3)) than healthy control subjects (1.15 +/- 0.15 cm(3)), though BPF was unable to distinguish between these 2 groups. MOV was smaller in patients with progressive MS (secondary- progressive MS, 0.88 +/- 0.19 cm(3) and primary-progressive MS, 0.95 +/- 0.30 cm(3)) than in patients with relapsing-remitting MS (1.08 +/- 0.15 cm(3)). A model including both MOV and BPF better predicted AI than BPF alone (P = .04). Good reproducibility in MOV measurements was demonstrated for intrarater (intraclass correlation coefficient, 0.97), interrater (0.79), and scan rescan data (0.81). CONCLUSION:MOV is associated with disability in MS and can serve as a biomarker of spinal cord damage.
RCT Entities:
BACKGROUND AND PURPOSE: While brain MR imaging is routinely performed, the MR imaging assessment of spinal cord pathology in multiple sclerosis (MS) is less frequent in clinical practice. The purpose of this study was to determine whether measurements of medulla oblongata volume (MOV) on routine brain MR imaging could serve as a biomarker of spinal cord damage and disability in MS. MATERIALS AND METHODS: We identified 45 patients with MS with both head and cervical spinal cord MR imaging and 29 age-matched and sex-matched healthy control subjects with head MR imaging. Disability was assessed by the expanded disability status scale (EDSS) and ambulation index (AI). MOV and upper cervical cord volume (UCCV) were manually segmented; semiautomated segmentation was used for brain parenchymal fraction (BPF). These measures were compared between groups, and linear regression models were built to predict disability. RESULTS: In the patients, MOV correlated significantly with UCCV (r = 0.67), BPF (r = 0.45), disease duration (r = -0.64), age (r = -0.47), EDSS score (r = -0.49) and AI (r = -0.52). Volume loss of the medulla oblongata was -0.008 cm(3)/year of age in patients with MS, but no significant linear relationship with age was found for healthy control subjects. The patients had a smaller MOV (mean +/- SD, 1.02 +/- 0.17 cm(3)) than healthy control subjects (1.15 +/- 0.15 cm(3)), though BPF was unable to distinguish between these 2 groups. MOV was smaller in patients with progressive MS (secondary- progressive MS, 0.88 +/- 0.19 cm(3) and primary-progressive MS, 0.95 +/- 0.30 cm(3)) than in patients with relapsing-remitting MS (1.08 +/- 0.15 cm(3)). A model including both MOV and BPF better predicted AI than BPF alone (P = .04). Good reproducibility in MOV measurements was demonstrated for intrarater (intraclass correlation coefficient, 0.97), interrater (0.79), and scan rescan data (0.81). CONCLUSION: MOV is associated with disability in MS and can serve as a biomarker of spinal cord damage.
Authors: G J Nijeholt; M A van Walderveen; J A Castelijns; J H van Waesberghe; C Polman; P Scheltens; P F Rosier; P J Jongen; F Barkhof Journal: Brain Date: 1998-04 Impact factor: 13.501
Authors: Xingchang Wei; Simon K Warfield; Kelly H Zou; Ying Wu; Xiaoming Li; Alexandre Guimond; John P Mugler; Randall R Benson; Leslie Wolfson; Howard L Weiner; Charles R G Guttmann Journal: J Magn Reson Imaging Date: 2002-02 Impact factor: 4.813
Authors: Geert Lycklama; Alan Thompson; Massimo Filippi; David Miller; Chris Polman; Franz Fazekas; Frederik Barkhof Journal: Lancet Neurol Date: 2003-09 Impact factor: 44.182
Authors: J C J Bot; F Barkhof; C H Polman; G J Lycklama à Nijeholt; V de Groot; E Bergers; H J Ader; J A Castelijns Journal: Neurology Date: 2004-01-27 Impact factor: 9.910
Authors: V L Stevenson; S M Leary; N A Losseff; G J Parker; G J Barker; Y Husmani; D H Miller; A J Thompson Journal: Neurology Date: 1998-07 Impact factor: 9.910
Authors: Christina Engl; Paul Schmidt; Milan Arsic; Christine C Boucard; Viola Biberacher; Michael Röttinger; Thorleif Etgen; Sabine Nunnemann; Nikolaos Koutsouleris; Maximilian Reiser; Eva M Meisenzahl; Mark Mühlau Journal: Neuroradiology Date: 2013-05-29 Impact factor: 2.804
Authors: Adam B Cohen; Mohit Neema; Ashish Arora; Elisa Dell'oglio; Ralph H B Benedict; Shahamat Tauhid; Daniel Goldberg-Zimring; Christian Chavarro-Nieto; Antonella Ceccarelli; Joshua P Klein; James M Stankiewicz; Maria K Houtchens; Guy J Buckle; David C Alsop; Charles R G Guttmann; Rohit Bakshi Journal: J Neuroimaging Date: 2011-03-29 Impact factor: 2.486
Authors: Laura Sander; Simon Pezold; Simon Andermatt; Michael Amann; Dominik Meier; Maria J Wendebourg; Tim Sinnecker; Ernst-Wilhelm Radue; Yvonne Naegelin; Cristina Granziera; Ludwig Kappos; Jens Wuerfel; Philippe Cattin; Regina Schlaeger Journal: Hum Brain Mapp Date: 2019-06-17 Impact factor: 5.038
Authors: Brett W Fling; Douglas N Martini; Eline Zeeboer; Andrea Hildebrand; Michelle Cameron Journal: Mult Scler Relat Disord Date: 2019-03-08 Impact factor: 4.339
Authors: M P Sampat; A M Berger; B C Healy; P Hildenbrand; J Vass; D S Meier; T Chitnis; H L Weiner; R Bakshi; C R G Guttmann Journal: AJNR Am J Neuroradiol Date: 2009-08-20 Impact factor: 3.825
Authors: Navid Shiee; Pierre-Louis Bazin; Kathleen M Zackowski; Sheena K Farrell; Daniel M Harrison; Scott D Newsome; John N Ratchford; Brian S Caffo; Peter A Calabresi; Dzung L Pham; Daniel S Reich Journal: PLoS One Date: 2012-05-15 Impact factor: 3.240